Hormone therapy and young-onset breast cancer

American Journal of Epidemiology

Volumn 181, Issue 10, 2015, Pages 799-807

  O'Brien, Katie M ^a   Fei, Chunyuan ^b   Sandler, Dale P ^a   Nichols, Hazel B ^c   Deroo, Lisa A ^a,d   Weinberg, Clarice R ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b ABBVIE INC   (United States)

^c University of North Carolina at Chapel Hill   (United States)

^d UNIVERSITY OF BERGEN   (Norway)

Author keywords

hormone therapy; propensity score; young onset breast cancer

Indexed keywords

ESTROGEN; GESTAGEN;

CANCER; COHORT ANALYSIS; DISEASE TREATMENT; HEALTH RISK; HORMONE;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; EXPOSURE; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; ONSET AGE; POSTMENOPAUSE; PROPENSITY SCORE; ADVERSE EFFECTS; AGED; BREAST NEOPLASMS; CASE CONTROL STUDY; ESTROGEN THERAPY; GENETICS; PREMENOPAUSE; RISK FACTOR; SIBLING;

ADULT; AGE OF ONSET; AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MIDDLE AGED; PREMENOPAUSE; PROGESTINS; PROPENSITY SCORE; RISK FACTORS; SIBLINGS;

EID: 84929587162     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwu347     Document Type: Article

References (43)

1. American Cancer Society. Cancer Facts and Figures 2013. Atlanta, GA: American Cancer Society; 2013.
2. American Cancer Society. Breast Cancer Facts and Figures, 2011-2012. Atlanta, GA: American Cancer Society; 2011.
3. Amadou A, Ferrari P, Muwonge R, et al. Overweight, obesity and risk of premenopausal breast cancer according to ethnicity: a systematic review and dose-response meta-analysis. Obes Rev. 2013;14(8):665-678.
4. Michels KB, Terry KL, Willett WC. Longitudinal study on the role of body size in premenopausal breast cancer. Arch Intern Med. 2006;166(21):2395-2402.
5. van den Brandt PA, Spiegelman D, Yaun SS, et al. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol. 2000;152(6): 514-527.
6. Iwasaki M, Otani T, Inoue M, et al. Role and impact of menstrual and reproductive factors on breast cancer risk in Japan. Eur J Cancer Prev. 2007;16(2):116-123.
7. Ewertz M. Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. Int J Cancer. 1988;42(6):832-838.
8. Clavel-Chapelon F; E3N-EPIC Group. Differential effects of reproductive factors on the risk of pre-and postmenopausal breast cancer. Results from a large cohort of French women. Br J Cancer. 2002;86(5):723-727.
9. Anderson WF, Chen BE, Brinton LA, et al. Qualitative age interactions (or effect modification) suggest different cancer pathways for early-onset and late-onset breast cancers. Cancer Causes Control. 2007;18(10):1187-1198.
10. Keegan TH, DeRouen MC, Press DJ, et al. Occurrence of breast cancer subtypes in adolescent and young adult women. Breast Cancer Res. 2012;14(2):R55.
11. Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362(9382):419-427.
12. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52, 705 women with breast cancer and 108, 411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet. 1997;350(9084):1047-1059.
13. Chen CL, Weiss NS, Newcomb P, et al. Hormone replacement therapy in relation to breast cancer. JAMA. 2002;287(6): 734-741.
14. Chlebowski RT, Manson JE, Anderson GL, et al. Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative observational study. J Natl Cancer Inst. 2013;105(8):526-535.
15. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 1995;332(24): 1589-1593.
16. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;107(1):103-111.
17. Li CI, Malone KE, Porter PL, et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA. 2003;289(24):3254-3263.
18. Newcomb PA, Titus-Ernstoff L, EganKM, et al. Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11(7):593-600.
19. Porch JV, Lee IM, Cook NR, et al. Estrogen-progestin replacement therapy and breast cancer risk: the Women's Health Study (United States). Cancer Causes Control. 2002; 13(9):847-854.
20. Ross RK, Paganini-Hill A, Wan PC, et al. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst. 2000;92(4): 328-332.
21. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.
22. Weiss NS, Szekely DR, English DR, et al. Endometrial cancer in relation to patterns of menopausal estrogen use. JAMA. 1979; 242(3):261-264.
23. Anderson GL, Chlebowski RT, Aragaki AK, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol. 2012;13(5):476-486.
24. Magnusson C, Baron JA, Correia N, et al. Breast-cancer risk following long-term oestrogen-and oestrogen-progestinreplacement therapy. Int J Cancer. 1999;81(3):339-344.
25. Brinton LA, Schairer C, Hoover RN, et al. Menstrual factors and risk of breast cancer. Cancer Invest. 1988;6(3): 245-254.
26. Ewertz M, Mellemkjaer L, Poulsen AH, et al. Hormone use for menopausal symptoms and risk of breast cancer. A Danish cohort study. Br J Cancer. 2005;92(7):1293-1297.
27. Kawai M, Minami Y, Kuriyama S, et al. Reproductive factors, exogenous female hormone use and breast cancer risk in Japanese: the Miyagi Cohort Study. Cancer Causes Control. 2010;21(1):135-145.
28. Nelson HD, Zakher B, Cantor A, et al. Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. Ann Intern Med. 2012;156(9):635-648.
29. Palmer JR, Rosenberg L, Clarke EA, et al. Breast cancer risk after estrogen replacement therapy: results from the Toronto Breast Cancer Study. Am J Epidemiol. 1991;134(12):1386-1395.
30. Shantakumar S, Terry MB, Paykin A, et al. Age and menopausal effects of hormonal birth control and hormone replacement therapy in relation to breast cancer risk. Am J Epidemiol. 2007;165(10):1187-1198.
31. Hall IJ, Moorman PG, Millikan RC, et al. Comparative analysis of breast cancer risk factors among African-American women and White women. Am J Epidemiol. 2005;161(1):40-51.
32. D'Aloisio AA, DeRoo LA, Baird DD, et al. Prenatal and infant exposures and age at menarche. Epidemiology. 2013;24(2): 277-284.
33. Fei C, DeRoo LA, Sandler DP, et al. Fertility drugs and young-onset breast cancer: results from the Two Sister Study. J Natl Cancer Inst. 2012;104(13):1021-1027.
34. National Institute of Environmental Health Sciences. The Sister Study, Baseline Data Collection. http://sisterstudy.niehs.nih. gov/English/baseline.htm. Accessed August 25, 2014.
35. Sprague BL, Trentham-Dietz A, Cronin KA. A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999-2010. Obstet Gynecol. 2012;120(3):595-603.
36. Månsson R, Joffe MM, SunW, et al. On the estimation and use of propensity scores in case-control and case-cohort studies. Am J Epidemiol. 2007;166(3):332-339.
37. Brookhart MA, Schneeweiss S, Rothman KJ, et al. Variable selection for propensity score models. Am J Epidemiol. 2006; 163(12):1149-1156.
38. Stürmer T, Joshi M, Glynn RJ, et al. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol. 2006;59(5):437-447.
39. Nichols HB, Visvanathan K, Newcomb PA, et al. Bilateral oophorectomy in relation to risk of postmenopausal breast cancer: confounding by nonmalignant indications for surgery? Am J Epidemiol. 2011;173(10):1111-1120.
40. North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause. 2012;19(3):257-271.
41. Parazzini F, Braga C, La Vecchia C, et al. Hysterectomy, oophorectomy in premenopause, and risk of breast cancer. Obstet Gynecol. 1997;90(3):453-456.
42. Press DJ, Sullivan-Halley J, Ursin G, et al. Breast cancer risk and ovariectomy, hysterectomy, and tubal sterilization in the women's contraceptive and reproductive experiences study. Am J Epidemiol. 2011;173(1):38-47.
43. Fei C, DeRoo LA, Sandler DP, et al. Menopausal symptoms and the risk of young-onset breast cancer. Eur J Cancer. 2013; 49(4):798-804.